Ally Bridge Group led a $68m funding round in Epicrispr Biotechnologies.

Ally Bridge Group, a global healthcare manager focused on high-impact life science innovation across private and public markets, led a $68m funding round in Epicrispr Biotechnologies, a biotechnology company, with participation from Solve FSHD. “We are developing a first-in-class, one-time epigenetic therapy that targets the genetic root cause of FSHD. The Series B financing and regulatory clearance to begin our first-in-human trial marks a pivotal milestone as we become a clinical-stage company. With a strong investor syndicate and recent FDA designations recognizing EPI-321’s potential, our team is laser-focused on advancing EPI-321 into the clinic to provide a much-needed therapy to patients and families in desperate need,” Amber Salzman, Epicrispr Biotechnologies CEO.